Skip to content
BOLUS

Signal from the log

BigHat Biosciences

75 M$ · Series C · United States · Biotech

BigHat Biosciences conçoit des anticorps en bouclant un modèle d'apprentissage avec un laboratoire automatisé à haut débit : la machine propose une séquence, le banc la teste, le résultat réentraîne le modèle. Son premier candidat, BHB810, un anticorps conjugué dirigé contre CDH17, est en phase 1 dans le cancer gastrique, premier patient traité. La société le décrit comme l'un des premiers biologiques conçus par IA à atteindre l'humain.

Article

Announced on , logged by the watch of 24 September 2026.

Operation
Funding round
Announced amount
75 M$
Stage
Series C
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Sujet traité. L'article donne les sources et la position de Bolus.

The investors

Led by DFJ Growth , Premji Invest , with Catalio Capital Management , LG Technology Ventures , Sigmas Group

Read the article on this operation (in French)

Provenance
Source businesswire
Logged on 24 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).